Of all the functions involved in a clinical trial, biostatistics is probably the most misunderstood by people outside the field. It’s often treated as a downstream service, something that happens after the “real” trial is finished, when someone runs the numbers and produces the results section. That framing gets the sequence backwards. A biostatistician’s most important work usually happens before a single patient is enrolled, not after the last one completes their final visit.
Biostatistics services shape whether a trial can actually answer its research question, whether its findings will hold up to regulatory scrutiny, and whether the resources spent running it were used efficiently. This guide covers what biostatistics actually involves across a trial’s lifecycle, and what tends to separate a strong biostatistics partner from one that’s only equipped to run the final analysis.
Biostatistics Touches Three Distinct Stages of a Trial
It’s useful to think of biostatistics services as three connected phases rather than one activity called “the analysis.”
1. Design Stage: Before Enrolment Begins
This is where a trial’s scientific and statistical foundation gets set, and mistakes here are extremely difficult to correct later.
Sample size calculation. Determining how many participants a trial needs to reliably detect a meaningful effect, based on the expected effect size, variability, and the level of statistical confidence required. Underpowered trials risk a false negative, missing a real effect simply because there weren’t enough participants to detect it statistically. Oversized trials waste time, money, and, in a medical context, expose more participants to investigational treatment than necessary
Randomisation design. Deciding how participants are assigned to treatment groups: simple randomisation, stratified randomisation, block randomisation to minimise bias and ensure treatment groups are comparable at baseline.
Statistical analysis plan (SAP). A detailed, pre-specified document describing exactly how the trial’s data will be analysed: which statistical tests, which populations (intent-to-treat, per-protocol), how missing data will be handled, and how multiplicity will be managed if there are multiple endpoints or comparisons. This document is finalised before the data is unblinded, which is what protects a trial’s conclusions from the appearance or the reality of after-the-fact data manipulation.
A biostatistics team involved at this stage can also flag design problems early: an endpoint that isn’t statistically well-suited to the trial’s timeline, an unrealistic sample size given site recruitment capacity, or a randomisation scheme that will create imbalance in a trial with multiple sites of very different sizes.
2. Conduct Stage: While the Trial Is Running
Interim analyses. Pre-planned looks at accumulating data, often used to assess safety, futility, or early efficacy signals in longer trials. These require careful statistical planning, since looking at data multiple times increases the risk of a false positive finding unless the analysis accounts for it.
Data monitoring committee (DMC) support. Independent committees overseeing participant safety in ongoing trials, particularly for longer or higher-risk studies, rely on biostatisticians to prepare unblinded interim data in a way that protects the integrity of the ongoing trial while still giving the committee what it needs to make safety recommendations.
Ongoing data review. Ideally, biostatisticians stay engaged throughout conduct, not just at the two bookends, reviewing accumulating data for patterns that might indicate a data quality issue rather than a genuine clinical signal.
3. Reporting Stage: After Database Lock
Clinical trial statistical analysis. Once the database is locked, the pre-specified statistical analysis plan is executed against the final, clean dataset, producing tables, listings, and figures (TLFs) covering efficacy, safety, and demographic summaries.
Regulatory-ready output. These TLFs feed directly into the clinical study report and the regulatory submission, typically structured to CDISC standards (ADaM datasets, specifically, for analysis-ready data).
The strongest biostatistics teams treat this stage as execution of a plan that was largely decided months or years earlier, not as the point where analytical decisions get made. If major analytical choices are still being debated after the database locks, that’s usually a sign the design-stage work wasn’t thorough enough.
Why Sample Size Calculation Deserves More Attention Than It Gets
Sample size calculation often gets treated as a formality: a number the biostatistician plugs into a template and hands back. In practice, it’s one of the highest-leverage decisions in the entire trial, because it directly determines the trial’s ability to detect the effect it’s actually looking for.
A defensible sample size calculation requires realistic assumptions about effect size and variability, usually drawn from prior studies, pilot data, or published literature, not optimistic guesses that make the required sample size look more achievable. A biostatistics partner who pushes back on overly optimistic assumptions during this stage, even when it means a larger and more expensive trial, is generally doing the sponsor a favour: an underpowered trial that fails to detect a real effect wastes far more than the cost of adequate enrolment.
The Statistical Analysis Plan: Why Pre-Specification Matters So Much
The statistical analysis plan is worth dwelling on because it’s the document that most directly protects a trial’s scientific credibility. Everything in it which population will be analysed, how missing data is handled, which statistical tests will be used, how multiple comparisons are managed is decided and locked before anyone sees unblinded results.
This matters because clinical data, especially in smaller or more complex trials, can often be analysed multiple defensible ways, and different analytical choices can produce different conclusions. Pre-specifying the analysis approach before seeing results removes the possibility, real or perceived, that the analysis method was selected because it produced a favourable outcome. Regulators scrutinise SAPs closely for exactly this reason, and a trial whose reported analysis deviates meaningfully from its pre-specified plan without clear justification tends to draw exactly the kind of scrutiny sponsors want to avoid.
Where Biostatistics Intersects with Data Management and Medical Writing
Biostatistics doesn’t operate in isolation, and trials tend to run more smoothly when it isn’t treated that way.
- With data management: the CRF and eCRF should be built with direct input from biostatistics, since the analysis plan determines exactly which variables, in which format, are actually needed. Designing forms without this input often means discovering mid-study that a needed variable wasn’t captured in a usable format.
- With medical writing: the clinical study report has to match the statistical output precisely. Writers working closely with the biostatistics team, rather than from a static output package, produce reports with far fewer internal inconsistencies.
- With regulatory affairs: analysis datasets structured to CDISC ADaM standards from the start make the eventual regulatory submission substantially smoother than retrofitting non-standard data late in the process.
What to Ask a Biostatistics Partner
A few questions tend to reveal more about a biostatistics team’s actual capability than a general list of software and credentials:
- Are they involved from the protocol and sample size stage, or only brought in once data collection is complete?
- Can they walk through how they handled a real interim analysis and DMC interaction on a past trial?
- How do they handle missing data in the statistical analysis plan, and is that approach pre-specified rather than decided after the fact?
- Do they build ADaM-compliant analysis datasets as standard practice?
- How closely do they work with data management on eCRF design, and with medical writing on the clinical study report?
Frequently Asked Questions
What are biostatistics services in clinical research? Biostatistics services cover the statistical design, monitoring, and analysis of a clinical trial, including sample size calculation, randomisation design, the statistical analysis plan, interim analyses, and the final clinical trial statistical analysis after database lock.
Why is sample size calculation so important? Sample size determines whether a trial has enough statistical power to reliably detect a real treatment effect. An underpowered trial risks a false negative, while an oversized trial wastes resources and unnecessarily exposes more participants to investigational treatment.
What is a statistical analysis plan (SAP)? A statistical analysis plan is a detailed document, finalised before data is unblinded, that pre-specifies exactly how a trial’s data will be analysed, including statistical tests, analysis populations, and handling of missing data. Pre-specification protects the trial’s findings from the appearance of after-the-fact data manipulation.
What is an interim analysis? An interim analysis is a pre-planned look at a trial’s accumulating data before the trial is complete, typically used to assess safety, futility, or early efficacy signals. It requires careful statistical planning to avoid inflating the risk of a false positive result.
Why should biostatistics be involved before a trial starts, not just at the end? Sample size, randomisation, and the statistical analysis plan all need to be defined at the design stage. A biostatistics team involved only after data collection is complete has no ability to influence these decisions, even though they determine whether the trial can actually answer its research question.
What is the difference between clinical trial statistical analysis and a statistical analysis plan? The statistical analysis plan is the pre-specified document describing how analysis will be conducted. Clinical trial statistical analysis is the execution of that plan against the final, locked dataset, producing the tables and figures used in the clinical study report and regulatory submission.
Leave a Reply